A recent review in Clinical Advances in Hematology & Oncology spotlights promising developments in gastrointestinal oncology — especially for colorectal and pancreatic cancers, where late-stage diagnoses have long limited options. Highlights include fruquintinib for refractory metastatic CRC, the tucatinib + trastuzumab combination for HER2-positive CRC, and expanded uses for trifluridine-tipiracil in combination regimens.
Trending
- Finding freedom as a physician through entrepreneurship (American Medical Association)
- Regulatory burdens continue to mount for physician practices (Fierce Healthcare)
- The unconventional players in the physician acquisition game (Becker’s ASC Review)
- Why Gastroenterology Is One of the Most In-Demand Locums Specialties (Hayes Locums)
- Snailing colorectal cancer drug delivery, once and for all (BioTechniques)
- Goodbye colonoscopy? New stool test detects 90% of colorectal cancers (Science Daily)
- CBT for IBS: A Frontline Treatment, Not Adjunct Therapy (Gastroenterology Advisor)
- Clinical practice update: Electrosurgery guidance refines endoscopy practice (GI & Hepatology News)
